{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:18:23Z","timestamp":1780589903384,"version":"3.54.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016126","name":"Beijing Hospital Authority","doi-asserted-by":"publisher","award":["DFL20241803"],"award-info":[{"award-number":["DFL20241803"]}],"id":[{"id":"10.13039\/100016126","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009331","name":"Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support","doi-asserted-by":"publisher","award":["ZLRK202301"],"award-info":[{"award-number":["ZLRK202301"]}],"id":[{"id":"10.13039\/501100009331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2603505"],"award-info":[{"award-number":["2022YFC2603505"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2306901"],"award-info":[{"award-number":["2023YFC2306901"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2308105"],"award-info":[{"award-number":["2023YFC2308105"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2603500"],"award-info":[{"award-number":["2022YFC2603500"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005088","name":"Beijing Municipal Health Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005088","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virologica Sinica"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.virs.2025.06.008","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T20:42:44Z","timestamp":1751661764000},"page":"579-586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical outcomes after HBsAg clearance in chronic hepatitis B patients treated with Peg-IFN \u03b1: A study with an 11- to 173-month follow-up"],"prefix":"10.1016","volume":"40","author":[{"given":"Wen","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxiao","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linmei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuojie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4241-8205","authenticated-orcid":false,"given":"Wei","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5622-1959","authenticated-orcid":false,"given":"Linqing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4108-7037","authenticated-orcid":false,"given":"Yao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3233-5473","authenticated-orcid":false,"given":"Minghui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virs.2025.06.008_bib1","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jhep.2004.10.026","article-title":"Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance","volume":"42","author":"Ahn","year":"2005","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virs.2025.06.008_bib2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s12876-021-02038-3","article-title":"FIB-4, APRI, and AST\/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran","volume":"21","author":"Amernia","year":"2021","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.virs.2025.06.008_bib3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cgh.2020.05.041","article-title":"Association between seroclearance of hepatitis B surface antigen and long-term clinical outcomes of patients with chronic hepatitis B virus infection: systematic review and meta-analysis","volume":"19","author":"Anderson","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2 Suppl. l","key":"10.1016\/j.virs.2025.06.008_bib4","first-page":"43","article-title":"Collagenases and liver fibrosis","volume":"22","author":"Arthur","year":"1995","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virs.2025.06.008_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116520","article-title":"An inducible sphingosine kinase 1 in hepatic stellate cells potentiates liver fibrosis","volume":"229","author":"Baek","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"Suppl. 1","key":"10.1016\/j.virs.2025.06.008_bib6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/liv.12710","article-title":"Reversibility of hepatitis B virus cirrhosis after therapy: who and why?","volume":"35","author":"Bedossa","year":"2015","journal-title":"Liver Int."},{"key":"10.1016\/j.virs.2025.06.008_bib7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S2468-1253(16)30189-3","volume":"2","author":"Bourli\u00e8re","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.virs.2025.06.008_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2023.102257","article-title":"Sustained response and HBsAg loss after nucleo(s)tide analogue discontinuation in chronic hepatitis B patients: the prospective SNAP study","volume":"48","author":"Brakenhoff","year":"2024","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.virs.2025.06.008_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1067362","article-title":"Functional molecular expression of nature killer cells correlated to HBsAg clearance in HBeAg-positive chronic hepatitis B patients during PEG-IFN \u03b1-2a therapy","volume":"13","author":"Cao","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.virs.2025.06.008_bib10","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1053\/gast.2002.36026","article-title":"Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection","volume":"123","author":"Chen","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virs.2025.06.008_bib11","first-page":"401","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (2022 version)","volume":"15","year":"2022","journal-title":"Chin J Clin Infect Dis"},{"key":"10.1016\/j.virs.2025.06.008_bib12","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.cgh.2020.09.004","article-title":"Ultra-Long-term follow-up of interferon alfa treatment for HBeAg-positive chronic hepatitis B virus infection","volume":"19","author":"Choi","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.virs.2025.06.008_bib13","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.3390\/v14122668","article-title":"Clinical outcomes and quantitative HBV surface antigen levels in diverse chronic hepatitis B patients in Canada: a retrospective real-world study of CHB in Canada (REVEAL-CANADA)","volume":"14","author":"Coffin","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.virs.2025.06.008_bib14","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virs.2025.06.008_bib15","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/jvh.13918","article-title":"Addition of PEG-interferon to long-term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg-negative chronic hepatitis B: multicentre Randomized Trial (PAS Study)","volume":"31","author":"Farag","year":"2024","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.virs.2025.06.008_bib16","first-page":"1629","article-title":"Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis","volume":"71","author":"Hall","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.virs.2025.06.008_bib17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-pathol-011110-130246","article-title":"Pathogenesis of liver fibrosis","volume":"6","author":"Hernandez-Gea","year":"2011","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.virs.2025.06.008_bib18","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.14309\/ajg.0000000000002759","article-title":"Limited sustained remission after nucleos(t)ide analog withdrawal: results from a large, global, multiethnic cohort of patients with chronic hepatitis B (RETRACT-B study)","volume":"119","author":"Hirode","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.virs.2025.06.008_bib19","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3350\/cmh.2022.0434","article-title":"Hepatitis B core-related antigen: a novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy","volume":"29","author":"Inoue","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.virs.2025.06.008_bib20","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1172\/JCI1018","article-title":"Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors","volume":"102","author":"Iredale","year":"1998","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.virs.2025.06.008_bib21","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/apt.18147","article-title":"Clinical trial: an open-label, randomised trial of different re-start strategies after treatment withdrawal in HBeAg negative chronic hepatitis B","volume":"60","author":"Johannessen","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.virs.2025.06.008_bib22","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jhep.2012.10.025","article-title":"Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis","volume":"58","author":"Kumada","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virs.2025.06.008_bib23","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/liv.14701","article-title":"Sustained off therapy response after peglyated interferon favours functional cure and no disease progression in chronic hepatitis B","volume":"41","author":"Lee","year":"2021","journal-title":"Liver Int."},{"key":"10.1016\/j.virs.2025.06.008_bib24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4103\/0366-6999.221275","article-title":"Plasmacytoid dendritic cell function and cytokine network profiles in patients with acute or chronic hepatitis B virus infection","volume":"131","author":"Li","year":"2018","journal-title":"Chin Med J (Engl)."},{"key":"10.1016\/j.virs.2025.06.008_bib25","first-page":"443","article-title":"Changes in the cytokine profiles of patients with chronic hepatitis B during antiviral therapy","volume":"34","author":"Li","year":"2021","journal-title":"Biomed. Environ. Sci."},{"key":"10.1016\/j.virs.2025.06.008_bib26","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.virs.2022.03.001","article-title":"Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients","volume":"37","author":"Li","year":"2022","journal-title":"Virol. Sin."},{"key":"10.1016\/j.virs.2025.06.008_bib27","article-title":"An optimized mode of interferon intermittent therapy help improve HBsAg disappearance in chronic hepatitis B patients","volume":"13","author":"Li","year":"2022","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.virs.2025.06.008_bib28","doi-asserted-by":"crossref","first-page":"593","DOI":"10.5009\/gnl240023","article-title":"Toward a functional cure for hepatitis B","volume":"18","author":"Lok","year":"2024","journal-title":"Gut Liver"},{"key":"10.1016\/j.virs.2025.06.008_bib29","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/liv.14155","article-title":"Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection","volume":"39","author":"Marcellin","year":"2019","journal-title":"Liver Int."},{"key":"10.1016\/j.virs.2025.06.008_bib30","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/hepr.14056","article-title":"A nation-wide medical record database study: value of hepatitis B surface antigen loss in chronic hepatitis B patients in Japan","volume":"54","author":"Okada","year":"2024","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.virs.2025.06.008_bib31","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/liv.14801","article-title":"Outcome of Chinese patients with hepatitis B at 96 weeks after functional cure with IFN versus combination regimens","volume":"41","author":"Pan","year":"2021","journal-title":"Liver Int."},{"key":"10.1016\/j.virs.2025.06.008_bib32","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000290","article-title":"Risk and risk score performance of hepatocellular carcinoma development in patients with hepatitis B surface antigen seroclearance","volume":"12","author":"Park","year":"2021","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.virs.2025.06.008_bib33","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/liv.13253","article-title":"Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients","volume":"36","author":"Su","year":"2016","journal-title":"Liver Int."},{"key":"10.1016\/j.virs.2025.06.008_bib34","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.cgh.2023.11.017","article-title":"Regression of liver fibrosis in patients on hepatitis B therapy is associated with decreased liver-related events","volume":"22","author":"Sun","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.virs.2025.06.008_bib35","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.virs.2025.06.008_bib36","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jhep.2022.12.018","article-title":"A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B","volume":"78","author":"van B\u00f6mmel","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virs.2025.06.008_bib37","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues","volume":"70","author":"Yip","year":"2019","journal-title":"J. Hepatol."}],"container-title":["Virologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1995820X25000926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1995820X25000926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:35:41Z","timestamp":1762598141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1995820X25000926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1995820X25000926"],"URL":"https:\/\/doi.org\/10.1016\/j.virs.2025.06.008","relation":{},"ISSN":["1995-820X"],"issn-type":[{"value":"1995-820X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes after HBsAg clearance in chronic hepatitis B patients treated with Peg-IFN \u03b1: A study with an 11- to 173-month follow-up","name":"articletitle","label":"Article Title"},{"value":"Virologica Sinica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virs.2025.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd\u00e9","name":"copyright","label":"Copyright"}]}}